Stifel Reiterates Reiterates Dyne Therapeutics (DYN) at Buy, DMD Trial Hold Remains Biggest Concern
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $29.00 price target on Dyne Therapeutics (NASDAQ: DYN), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
